Literature DB >> 22131272

Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1.

Michael P Whyte1, Deborah Wenkert, Jennifer L Demertzis, Edward F DiCarlo, Erica Westenberg, Steven Mumm.   

Abstract

Fibrodysplasia ossificans progressiva (FOP) is the rare mendelian disease characterized by congenital malformation of the great toes preceding heterotopic ossification (HO) and caused by heterozygous activating mutation of the ACVR1 gene, which encodes the ALK2 receptor for bone morphogenetic proteins. Early adult life is the latest reported presentation for the HO of FOP. The patient of our report first developed HO from FOP at 47 years of age. She had congenital hallux valgus deformity but despite various traumas was previously well. HO began several months after a brief, seemingly viral, illness. Sudden and progressive pain, redness, warmth, and swelling appeared over a scapula. Computed tomography was remarkable for asymmetrical thickening of muscles and fascial planes. At first, the significance of the great toe abnormalities went unrecognized elsewhere, and biopsy for suspected inflammatory fasciitis revealed proliferating fibroblasts with scattered inflammatory cells. Prednisone improved her symptoms but, when tapered, swellings developed on her chest, posterior thorax, and flank, and FOP was diagnosed. Methylprednisolone, methotrexate, and alendronate seemed to help her symptoms, but the lesions worsened and HO appeared and rapidly progressed. Mutation analysis of the ACVR1 gene revealed heterozygosity for a unique missense defect (c.974G>C, p.G325A) that predicted a conservative (mild) amino acid change within the kinase domain of ALK2. Hence, HO in FOP can be delayed until middle-age, and perhaps provoked by a viral illness. Nevertheless, progression of HO can then be rapid despite bisphosphonate and high-dose immunosuppressive therapy. Possibly, our patient's late-onset HO reflects her mild alteration of ALK2 or some protective and therapeutically useful genetic, epigenetic, or nongenetic factor. Recognition of presymptomatic individuals or late-onset HO in FOP should have these patients avoid traumas, treatments, and maybe viral illnesses that can initiate or exacerbate the HO. If the diagnosis of FOP is unclear, ACVR1 mutation analysis is available at certified laboratories.
© 2012 American Society for Bone and Mineral Research

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22131272     DOI: 10.1002/jbmr.1473

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  17 in total

1.  Myositis ossificans in children: a review.

Authors:  N K Sferopoulos; R Kotakidou; A S Petropoulos
Journal:  Eur J Orthop Surg Traumatol       Date:  2017-03-09

Review 2.  Fibrodysplasia ossificans progressiva: Basic understanding and experimental models.

Authors:  Zijuan Qi; Jing Luan; Xiaoyan Zhou; Yazhou Cui; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2017-11

3.  Shared ACVR1 mutations in FOP and DIPG: Opportunities and challenges in extending biological and clinical implications across rare diseases.

Authors:  Harry J Han; Payal Jain; Adam C Resnick
Journal:  Bone       Date:  2017-08-02       Impact factor: 4.398

Review 4.  Molecular and cellular mechanisms of heterotopic ossification.

Authors:  Diana M Ramirez; Melissa R Ramirez; Anthony M Reginato; Damian Medici
Journal:  Histol Histopathol       Date:  2014-05-05       Impact factor: 2.303

5.  Effectiveness and mode of action of a combination therapy for heterotopic ossification with a retinoid agonist and an anti-inflammatory agent.

Authors:  Sayantani Sinha; Kenta Uchibe; Yu Usami; Maurizio Pacifici; Masahiro Iwamoto
Journal:  Bone       Date:  2016-02-15       Impact factor: 4.398

6.  Mutant activin-like kinase 2 in fibrodysplasia ossificans progressiva are activated via T203 by BMP type II receptors.

Authors:  Mai Fujimoto; Satoshi Ohte; Kenji Osawa; Arei Miyamoto; Sho Tsukamoto; Takato Mizuta; Shoichiro Kokabu; Naoto Suda; Takenobu Katagiri
Journal:  Mol Endocrinol       Date:  2015-01

Review 7.  Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders.

Authors:  Maurizio Pacifici; Eileen M Shore
Journal:  Cytokine Growth Factor Rev       Date:  2015-12-28       Impact factor: 7.638

8.  Analysis of clinical manifestations and treatment in 26 children with fibrodysplasia ossificans progressiva in China.

Authors:  Jun-Mei Zhang; Cai-Feng Li; Shuang-Ying Ke; Yu-Rong Piao; Tong-Xin Han; Wei-Ying Kuang; Jiang Wang; Jiang-Hong Deng; Xiao-Hua Tan; Chao Li
Journal:  World J Pediatr       Date:  2019-09-16       Impact factor: 2.764

9.  Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.

Authors:  Apirat Chaikuad; Ivan Alfano; Georgina Kerr; Caroline E Sanvitale; Jan H Boergermann; James T Triffitt; Frank von Delft; Stefan Knapp; Petra Knaus; Alex N Bullock
Journal:  J Biol Chem       Date:  2012-09-12       Impact factor: 5.157

10.  From mysteries to medicines: drug development for fibrodysplasia ossificans progressive.

Authors:  Frederick S Kaplan; Robert J Pignolo; Eileen M Shore
Journal:  Expert Opin Orphan Drugs       Date:  2013-08       Impact factor: 0.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.